Announcement • Sep 17

Profusa, Inc. Receives Non-Compliance Letter from Nasdaq

On September 11, 2025, Profusa, Inc. (the Company") received a notice (the MVLS Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, based upon its review of the market value of listed securities (MVLS") of the Company's common stock, par value $0.0001 per share (the Common Stock"), from July 29, 2025 to September 10, 2025, the Company no longer meets Nasdaq Listing Rule 5450(b)(2)(A), which requires companies listed on the Nasdaq Global Market to maintain a minimum MVLS of $50,000,000. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until March 10, 2026, to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A). If at any time during this compliance period, the Common Stock's MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed, provided, however that Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) prior to the expiration of the compliance period, the Company will receive written notification that the Company's securities are subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel. Alternatively, the Company may consider applying to transfer the listing of the Company's securities to the Nasdaq Capital Market, provided that the Company then satisfies the requirements for continued listing on that market. The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements. On September 11, 2025, the Company received a second notice (the Bid Price Notice", and together with the MVLS Notice, the Notices") from Nasdaq notifying the Company that, based upon its review of the closing bid price of the Common Stock, from July 29, 2025 to September 10, 2025, the Company no longer meets Nasdaq Listing Rule 5450(a)(1), which requires companies listed on the Nasdaq Global Market to maintain a minimum bid price of $1.00 per share. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until March 10, 2026, to regain compliance with Nasdaq Listing Rule 5450(a)(1). If at any time during this compliance period, the Common Stock has a closing bid price bid price of at least $1.00 per share for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed, provided, however that Nasdaq may, in its discretion, require the Company to maintain the minimum bid price for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. In the event the Company does not regain compliance with Nasdaq Listing Rule 5450(a)(1) prior to the expiration of the compliance period, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided, among other things, the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Global Market, other than the minimum bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The Company is monitoring the minimum bid price of its listed securities and is considering available options to regain compliance with Nasdaq's continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(a)(1) or maintain compliance with other applicable Nasdaq listing requirements. The Notices have no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market, which will continue to trade under the symbol PFSA", subject to the Company's continued compliance with Nasdaq's other continued listing requirements.

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	0.2%
Management average tenure	1yr
Board average tenure	1yr

Name	Position	Tenure	Compensation	Ownership
Chung-Bin Hwang	President	no data	US$2.30m	0.24% $ 477.0
Fred Knechtel	Chief Financial Officer	1yr	US$851.60k	0.32% $ 626.5
Jack Stover	CEO & Executive Chairman	no data	no data	0.16% $ 312.7
William McMillan	Co-founder	no data	no data	0.18% $ 361.5
David Icke	Head of Digital Health Business	7.3yrs	no data	no data
Sean Givens	Head of Government Business	7.3yrs	no data	no data

Name	Position	Tenure	Compensation	Ownership
Jack Stover	CEO & Executive Chairman	1yr	no data	0.16% $ 312.7
Liviu Goldenberg	Independent Director	no data	no data	no data
Rajesh Asorpota	Independent Director	1yr	no data	no data
Haeyong Chung	Independent Director	1yr	no data	0.0086% $ 17.0
Peter O'Rourke	Lead Independent Director	1yr	no data	0.031% $ 60.4

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 12:36
End of Day Share Price	2026/07/31 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Profusa Management

Management criteria checks 0/4

Key information

Recent management updates

Profusa, Inc. Announces CEO Changes, Effective July 21, 2026

High number of new and inexperienced directors

Profusa, Inc., Annual General Meeting, Jun 04, 2026

Profusa, Inc. Appoints Fred Knechtel as CFO

Recent updates

Profusa, Inc. Announces CEO Changes, Effective July 21, 2026

High number of new and inexperienced directors

Profusa Submits Response Package to GMED as Part of Ongoing Ce Mark Review Process for Lumee Oxygen Platform

Profusa, Inc., Annual General Meeting, Jun 04, 2026

Profusa, Inc. Receives Notification from Nasdaq Regarding Failure to Regain Compliance with Listing Rule

Profusa, Inc. announced delayed annual 10-K filing

Profusa, Inc Announces Non-Compliance Notice from the Nasdaq Stock Market LLC

Profusa, Inc. Raises Revenue Guidance for 2026

Profusa, Inc. Presents Positive Us- Study Clinical Results At Leipzig Interventional Course (Linc) 2026

Profusa, Inc. Launches Lumee™? Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

Profusa, Inc. announced delayed 10-Q filing

Profusa, Inc. Announces Notice of Non-Compliance with Nasdaq Continued Listing

Profusa, Inc. Provides Earnings Guidance for the Year 2026, 2027 and 2030

Profusa, Inc. announced that it has received $1 million in funding

Profusa, Inc. Receives Non-Compliance Letter from Nasdaq

Profusa, Inc. Appoints Fred Knechtel as CFO

Profusa, Inc. announced that it expects to receive $100 million in funding from Ascent Partners Fund LLC

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources